You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK – Supported by $34 million in Series B funding announced earlier this week, glycoproteomics firm InterVenn Biosciences is targeting a launch of its pelvic mass triage test in the first half of 2021.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.